• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endo Pharmaceutical Holdings

Endo Pharmaceutical Holdings

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: These are the only 9 stocks Morningstar is fully bullish on

    UPDATE: These are the only 9 stocks Morningstar is fully bullish on

  2. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  3. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  4. Our Outlook for the Credit Markets

    The corporate bond market will probably struggle to return much above break-even in 2014.

  5. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  6. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

©2017 Morningstar Advisor. All right reserved.